Objective: To investigate the expression of programmed cell death factor 5 ( PDCD5) in patients with rheumatoid arthritis (RA) and to explore its potential role in the pathogenesis of RA. Methods: A total of 36 patients with RA and 35 patients with osteoarthritis (OA) were enrolled, and 33 healthy people were served as controls. PDCD5 and IL-6 levels in serum as well as the levels in synovial fluid were measured by enzyme-linked immunosorbent assay (ELISA). Indices including C reaction protein (CRP), erythrocyte sedimentation rate(ESR), rheumatoid factor(RF）and cyclic citrullinated protein (CCP）were also detected, while count of swollen joints (SJC) and count of tender joints (TJC) served as reference of disease activity were recorded. Results: Compared with OA patients and controls, RA patients had a higher serum level of PDCD5 [（32.47±12.79） ng/mL vs （12.79±9.84） ng/mL in OA and (18.40±18.97） ng/mL in controls]. PDCD5 levels in synovial fluid of RA patients were also higher than those of OA patients. Furthermore, serum level of PDCD5 in RA patients was negatively correlated with IL-6 level in serum, however, no correlation was observed in synovial fluid. Pearson analysis showed that serum PDCD5 level in RA was negatively correlated with CRP, ESR, TJC and SJC (R=-0.523, -0.701, -0.845, -0.943, respectively), but had no correlation with RF and CCP. Conclusions: Serum and synovial levels of PDCD5 could reflect the activity of RA, and its abnormal expression may be associated with level of IL-6.
YUAN Yiwei, GU Juanfang, FEI Zhangli, YANG Mingfeng, WANG Yiwen, WANG Hongzhi
. Level of programmed cell death factor 5 in patients with active rheumatoid arthritis[J]. Journal of Diagnostics Concepts & Practice, 2018
, 17(04)
: 453
-456
.
DOI: 10.16150/j.1671-2870.2018.04.019
[1] Yu C, Jin SY, Li MT, et al.Current status of rheumatoid arthritis registries and prevalence of remission[J]. Zhonghua Nei Ke Za Zhi,2018,57(3):175-178.
[2] Firestein GS.Evolving concepts of rheumatoid arthritis[J]. Nature,2003,423(6937):356-361.
[3] Wang W, Song XW, Zhao CH.Roles of programmed cell death protein 5 in inflammation and cancer(Review)[J]. Int J Oncol,2016,49(5):1801-1806.
[4] Jiang J, Wang N, Guan Z, et al.Programmed cell death 5 factor enhances triptolide-induced fibroblast-like synoviocyte apoptosis of rheumatoid arthritis[J]. Artif Cells Blood Substit Immobil Biotechnol,2010,38(1):38-42.
[5] Brzustewicz E, Bryl E.The role of cytokines in the pathogenesis of rheumatoid arthritis--Practical and potential application of cytokines as biomarkers and targets of personalized therapy[J]. Cytokine,2015,76(2):527-536.
[6] Braun J, Sieper J.Classification criteria for rheumatoid arthritis and ankylosing spondylitis[J]. Clin Exp Rheumatol,2009,27(4 Suppl 55):S68-S73.
[7] Zhang W, Doherty M, Peat G, et al.EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis[J]. Ann Rheum Dis,2010,69(3):483-489.
[8] Gu X, Gu B, Lv X, et al.1, 25-dihydroxy-vitamin D3 with tumor necrosis factor-alpha protects against rheumatoid arthritis by promoting p53 acetylation-mediated apoptosis via Sirt1 in synoviocytes[J]. Cell Death Dis,2016,7(10):e2423.
[9] Zhu A, Wang M, Zhou G, et al.Fas/FasL, Bcl2 and Caspase-8 gene polymorphisms in Chinese patients with rheumatoid arthritis[J]. Rheumatol Int,2016,36(6):807-818.
[10] Zhao M, Li Y, Xiao W.Anti-apoptotic effect of interleukin-22 on fibroblast-like synoviocytes in patients with rheumatoid arthritis is mediated via the signal transducer and activator of transcription 3 signaling pathway[J]. Int J Rheum Dis,2017,20(2):214-224.
[11] Leech M, Xue JR, Dacumos A, et al.The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response[J]. Clin Exp Immunol,2008,152(2):345-353.
[12] Jiang J, Wang N, Guan Z, et al.Programmed cell death 5 factor enhances triptolide-induced fibroblast-like synoviocyte apoptosis of rheumatoid arthritis[J]. Artif Cells Blood Substit Immobil Biotechnol,2010,38(1):38-42.
[13] Noack M, Miossec P.Selected cytokine pathways in rheumatoid arthritis[J]. Semin Immunopathol,2017,39(4):365-383.
[14] 刘娜, 徐建华. IL-6在类风湿关节炎合并系统损害中的作用机制研究进展[J]. 安徽医学,2017,38(5):658-661.
[15] 刘玮, 吴歆, 徐沪济. 类风湿关节炎易感基因遗传背景的研究进展[J]. 诊断学理论与实践,2018,17(3):347-351.
